Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies by unknown
Wang et al. Thrombosis Journal 2013, 11:25
http://www.thrombosisjournal.com/content/11/1/25ORIGINAL CLINICAL INVESTIGATION Open AccessRivaroxaban for the treatment of symptomatic
deep-vein thrombosis and pulmonary embolism
in Chinese patients: a subgroup analysis of the
EINSTEIN DVT and PE studies
Yuqi Wang1, Chen Wang2, Zhong Chen3, Jiwei Zhang4, Zhihong Liu5, Bi Jin6, Kejing Ying7, Changwei Liu8,
Yuxia Shao9, Zhicheng Jing10,11, Isabelle Ling Meng12, Martin H Prins13, Ákos F Pap14, Katharina Müller14,
Anthonie WA Lensing14* and for the Chinese EINSTEIN InvestigatorsAbstract
Background: The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute
symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this
setting, included patients in China. This analysis evaluates the results of these studies in this subgroup of patients.
Methods: A total of 439 Chinese patients who had acute symptomatic DVT (n=211), or PE with or without DVT
(n=228), were randomized to receive rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily) or
standard therapy of enoxaparin overlapping with and followed by an adjusted-dose vitamin K antagonist, for 3, 6,
or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal
safety outcome was major or non-major clinically relevant bleeding.
Results: The primary efficacy outcome occurred in seven (3.2%) of the 220 patients in the rivaroxaban group and in
seven (3.2%) of the 219 patients in the standard-therapy group (hazard ratio, 1.04; 95% confidence interval 0.36–3.0;
p=0.94). The principal safety outcome occurred in 13 (5.9%) patients in the rivaroxaban group and in 20 (9.2%)
patients in the standard-therapy group (hazard ratio, 0.63; 95% confidence interval 0.31–1.26; p=0.19). Major
bleeding was observed in no patients in the rivaroxaban group and in five (2.3%) patients in the standard-therapy
group. In fragile patients (defined as age >75 years, creatinine clearance <50 mL/min, and/or body weight ≤50 kg),
the principal safety outcome occurred in four (8.9%) of the 45 patients who received rivaroxaban compared with
seven (15.2%) of the 46 patients who received standard therapy.
Conclusions: In Chinese patients with acute symptomatic DVT and/or PE, rivaroxaban was as efficacious as
enoxaparin followed by vitamin K antagonist therapy, with a similar safety profile. The relative efficacy and safety of
rivaroxaban compared with enoxaparin/vitamin K antagonist were consistent with that found in the rest of the world.
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Acute venous thromboembolism (VTE; i.e. deep-vein
thrombosis [DVT] or pulmonary embolism [PE]) is a com-
mon disorder with an annual incidence in the Western
world of approximately 1–2 cases per 1000 persons in the
general population [1,2]. Short-term treatment of VTE is
effective and reduces the risk of recurrent disease, which is
the major complication, from an estimated 25% to approxi-
mately 3% during the first 6–12 months of therapy [3].
However, the risk of recurrent VTE remains after treatment
ends and can reach 5–10% during the first year [4,5].
Although the incidence of VTE in China is not known,
the disease is increasingly being recognized by the Chinese
healthcare system; this trend may arise as a result of
increasing physician attention and the availability of
minimally invasive and non-invasive diagnostic tools.
The results of VTE treatment among Chinese nationals
are not well documented, although there seems to be a
general belief that the risk of bleeding is high among
patients receiving standard treatment, and that vitamin
K antagonist (VKA) therapy should be dosed carefully with
a tendency towards lower international normalized ratio
(INR) values. Similar concerns about bleeding would also
apply to the direct oral anticoagulants.
Rivaroxaban is an orally active, direct Factor Xa inhibitor
with a rapid onset of action and predictable pharmacokinet-
ics and pharmacodynamics [6], which does not require rou-
tine coagulation monitoring, has no food interactions, and
has limited drug interactions. These properties have also
been confirmed through a rivaroxaban dose escalation study
in healthy, elderly Chinese subjects [7]. The EINSTEIN
DVT and EINSTEIN PE studies evaluated rivaroxaban for
the treatment of VTE. In this large, international, phase III
clinical program in more than 8000 patients with acute
symptomatic DVT and/or PE, monotherapy with rivaroxa-
ban was shown to be as effective as dual-drug therapy with
enoxaparin overlapping with and followed by VKA therapy,
with reduced occurrence of major bleeding [8–11]. In these
studies, for the first time, Chinese hospitals participated
using the same rivaroxaban regimen.
Here, we report the results of the 439 patients who




EINSTEIN DVT and EINSTEIN PE were randomized,
open-label studies that compared the efficacy and safety
of rivaroxaban with standard therapy, consisting of enoxa-
parin and adjusted-dose VKA, in patients with acute, symp-
tomatic DVT and/or PE [8–11]. Patients were eligible if
they were of legal age and had objectively confirmed acute,
symptomatic DVT and/or PE. Briefly, patients were
ineligible to participate if they had received a therapeuticdose of parenteral anticoagulant for more than 48 hours or
if they had received more than a single dose of a VKA be-
fore randomization; if thrombectomy had been performed,
a vena cava filter placed, or a fibrinolytic agent administered
for treatment of the current episode; or if they had any
contraindication listed in the local labeling of enoxaparin,
warfarin, or acenocoumarol. Other criteria for ineligibility
were, another indication for a VKA; creatinine clearance
(CrCl) <30 mL/min; clinically significant liver disease; active
bleeding or a high risk of bleeding contraindicating anti-
coagulant treatment; childbearing potential without proper
contraceptive measures; pregnancy or breast-feeding;
or a life expectancy of less than 3 months. Because the
metabolism of rivaroxaban is mediated by cytochrome
P450 3A4 (CYP3A4), CYP3A4 inhibitors can decrease
the metabolism of rivaroxaban, causing an increase in the
area under the plasma concentration–time curve (AUC)
and the maximum plasma concentration (Cmax); conversely,
CYP3A4 inducers can increase the metabolism of rivaroxa-
ban, thus decreasing the AUC and Cmax. Therefore, patients
requiring concomitant therapy of a strong inhibitor or
inducer of CYP3A4 were also ineligible.
Randomization and treatment regimens
Randomization was performed with the use of a com-
puterized voice-response system and was stratified ac-
cording to country and the intended treatment duration
(3, 6, or 12 months). The intended duration of treat-
ment was determined by the treating physician before
randomization. Patients who were assigned to the rivaroxa-
ban group were given 15 mg twice daily for the first 21 days,
followed by 20 mg once daily. Patients who were assigned
to the standard-therapy group received enoxaparin at a
dose of 1.0 mg/kg of body weight twice daily, and either
warfarin or acenocoumarol started within 48 hours after
randomization. Enoxaparin was discontinued when the
INR was ≥2.0 for 2 consecutive days and the patient had
received at least 5 days of enoxaparin treatment. The dose
of the VKA was adjusted to maintain an INR of 2.0–3.0.
The INR was determined at least once a month. The use of
non-steroidal anti-inflammatory drugs and antiplatelet
agents was discouraged. Aspirin administered at a dose
of no more than 100 mg per day, clopidogrel at a dose
of 75 mg per day, or both, were permitted.
Surveillance and follow-up
Patients were followed for the intended treatment period
and were assessed at fixed intervals, which were identical
for both treatment arms, using a checklist to elicit informa-
tion on symptoms and signs of recurrent VTE, bleeding,
and adverse events. Patients were instructed to report to
the study center immediately if any of these symptoms or
signs occurred. In the case of suspected VTE, the protocol
required objective testing.
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The primary efficacy outcome was symptomatic recurrent
VTE, which was defined as a composite of fatal and non-
fatal PE or DVT on the basis of criteria that have been de-
scribed previously. Death was classified as being due to PE,
bleeding, or other established diagnoses. PE was considered
the cause of death if there was objective documentation of
the condition, or if death could not be attributed to a docu-
mented cause and PE could not be confidently ruled out.
The principal safety outcome was clinically relevant
bleeding, which was defined as a composite of major and
clinically relevant non-major bleeding, as described previ-
ously [8,9]. Bleeding was defined as major if it was clinically
overt and: a) associated with a decrease in hemoglobin
level of ≥2.0 g/dL; b) led to the transfusion of ≥2 units of
red cells; c) was intracranial or retroperitoneal, or occurred
in another critical site; or d) contributed to death. Clinically
relevant non-major bleeding was defined as overt bleeding
that did not meet the criteria for major bleeding, but was as-
sociated with medical intervention, unscheduled contact
with a physician, interruption or discontinuation of a study
drug, or discomfort or impairment of activities of daily life.
Predefined secondary outcomes included major bleeding,
death from any cause, vascular events (acute coronary syn-
drome, ischemic stroke, transient ischemic attack, or sys-
temic embolism), and net clinical benefit (which was
defined as a composite of the primary efficacy outcome and
major bleeding, as assessed in the intention-to-treat
population). All suspected outcome events were classi-
fied by a central adjudication committee whose mem-
bers were unaware of the treatment assignments.
Statistical analysis
The primary efficacy analysis was performed on an
intention-to-treat basis with the use of a Cox proportional-
hazards model stratified according to the intended duration
of treatment and index event (DVT/PE), with adjustment
for the presence or absence of cancer at baseline. The
population for the safety analysis was defined as all patients
who received at least one dose of a study drug. Bleeding
events were included in the analysis if they occurred during
treatment or within 2 days after the last dose of a study
drug. Kaplan–Meier curves were generated to display the
distribution of bleeding over time. In addition, analyses of
the principal safety outcome in prespecified subgroups
were performed. The mean time during which the INR
was within the therapeutic range was calculated after
the discontinuation of enoxaparin, with correction for
interruptions in the administration of VKAs.
Results
Patients
From May 2008 through to March 2011, 439 patients were
enrolled at 21 sites in China (details of investigators andsites are listed in Additional file 1) 211 patients had DVT
only and 228 had PE with (n=67) or without DVT (n=161).
A total of 220 patients were assigned to receive rivaroxa-
ban, and 219 were assigned to receive enoxaparin and a
VKA (standard therapy). The characteristics of patients
were similar at baseline in the rivaroxaban and standard-
therapy groups (Table 1). One patient in each treatment
arm did not receive the assigned study treatment.
Treatment and follow-up
In the standard-therapy group, the median duration of
enoxaparin treatment was 9 days (interquartile range, 7–12),
and the INR at the end of enoxaparin treatment was ≥2.0 in
84.9% of patients. The mean percentage of time during
which the INR was in the therapeutic range (2.0–3.0) was
52.4%; the corresponding mean percentages for an INR >3.0
and <2.0 were 10.1% and 37.5%, respectively. The mean per-
centage of time within the therapeutic range ranged from
45.6% (during the third month) to 68.3% (during month 7).
In the rivaroxaban group, adherence to therapy was >80% in
93.2% of patients. As an event-driven study, termination
upon the required number of events resulted in treatment
duration being less than intended in 14 (6.4%) patients in
the rivaroxaban group and 11 (5.0%) patients in the
standard-therapy group. Four (1.8%) patients in the rivarox-
aban group and three (1.4%) patients in the standard-
therapy group were lost to follow-up (Table 2).
Clinical outcomes
The clinical outcomes are shown in Table 3. The primary
efficacy outcome occurred in seven (3.2%) of the 220 pa-
tients in the rivaroxaban group compared with seven (3.2%)
of the 219 patients in the standard-therapy group, for a haz-
ard ratio of 1.04 (95% confidence interval [CI] 0.36–3.0). By
day 21, at the end of twice-daily rivaroxaban administration,
the primary efficacy outcome had occurred in one (0.5%)
patient in the rivaroxaban group and in four (1.8%) patients
in the standard-therapy group.
The principal safety outcome, a first major or clinically
relevant non-major bleeding episode, occurred in 13 (5.9%)
of the 219 patients in the rivaroxaban group compared with
20 (9.2%) of the 218 patients in the standard-therapy group
(hazard ratio, 0.63; 95% CI 0.31–1.26; p=0.19) (Figure 1).
Major bleeding occurred in none of the patients in the
rivaroxaban group and in five (2.3%) patients in the
standard-therapy group. Of these five major bleeding
events, two were fatal.
Among patients who were older than 75 years, major
or clinically relevant non-major bleeding occurred in three
(9.1%) of the 33 rivaroxaban recipients compared with six
(21.4%) of the 28 standard-therapy recipients. In those
patients with CrCl <50 mL/min, this outcome occurred in
one (5.3%) and six (21.4%) of the 19 and 28 patients, re-
spectively. In frail patients (defined as age >75 years,
Table 1 Demographic and clinical characteristics: Chinese patients in the EINSTEIN DVT and EINSTEIN PE studies*
Characteristic Rivaroxaban (n=220) Standard therapy (n=219)
Mean age, years 58.6 ± 15.8 59.0 ± 15.0
Male sex, n (%) 127 (57.7) 112 (51.1)
Weight, n (%)
≤50 kg 11 (5.0) 15 (6.8)
>50–80 kg 182 (82.7) 188 (85.8)
>80 kg 25 (11.4) 16 (7.3)
Missing data 2 (0.9) 0
Creatinine clearance, n (%)
<30 mL/min 1 (0.5) 0
30–<50 mL/min 19 (8.6) 28 (12.8)
50–<80 mL/min 75 (34.1) 72 (32.9)
≥80 mL/min 117 (53.2) 116 (53.0)
Missing data 8 (3.6) 3 (1.4)
Diagnostic method, PE cohort, n (%)
Spiral computed tomography 99 (86.8) 102 (87.9)
Ventilation–perfusion lung scanning 11 (9.6) 10 (8.8)
Pulmonary angiography 3 (2.6) 1 (0.9)
Not confirmed/not evaluable 1 (0.9) 3 (2.6)
Anatomical extent of PE, n (%)
Limited: ≤25% of vasculature of a single lobe 13 (11.4) 10 (8.6)
Intermediate 67 (58.8) 73 (62.9)
Extensive: multiple lobes and >25% of entire pulmonary vasculature 30 (26.3) 29 (25.0)
Not assessable 4 (3.5) 4 (3.4)
Diagnostic method, DVT cohort, n (%)
Ultrasonography 130 (90.9) 120 (89.6)
Venography 1 (0.7) 3 (2.2)
Computed tomography scan 4 (2.8) 1 (0.7)
Not confirmed/not evaluable 6 (4.2) 9 (6.7)
Anatomical extent of proximal DVT, n (%)
Limited (popliteal vein or more distal) 25 (17.5) 17 (12.7)
Intermediate (most proximal: superficial femoral vein) 25 (17.5) 27 (20.1)
Extensive (most proximal: common femoral or iliac vein) 112 (78.3) 108 (80.6)
Time from onset of symptoms to randomization, days
Median 9.0 9.0
Interquartile range 4.0–19.0 4.0–20.0
Cause of DVT or PE, n (%)†
Unprovoked 164 (74.5) 162 (74.0)
Secondary DVT or PE 56 (25.5) 57 (26.0)
Recent surgery or trauma 34 (15.5) 39 (17.8)
Immobilization 21 (9.5) 24 (11.0)
Estrogen therapy 2 (0.9) 4 (1.8)
Wang et al. Thrombosis Journal 2013, 11:25 Page 4 of 8
http://www.thrombosisjournal.com/content/11/1/25
Table 1 Demographic and clinical characteristics: Chinese patients in the EINSTEIN DVT and EINSTEIN PE studies*
(Continued)
Active cancer 6 (2.7) 7 (3.2)
Puerperium 2 (0.9) 4 (1.8)
Previous DVT or PE 27 (12.3) 36 (16.4)
*Plus–minus values are means ± SD. There were no significant differences between the two study groups. Percentages may not total 100 because of rounding.
†Patients could have multiple causes of DVT or PE.
DVT, deep-vein thrombosis; PE, pulmonary embolism; SD, standard deviation.




Intention-to-treat population, n 220 219
Recurrent VTE, n (%) 7 (3.2) 7 (3.2)
Type of first recurrent VTE, n
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clinically relevant non-major bleeding occurred in four
(8.9%) of the 45 rivaroxaban patients compared with seven
(15.2%) of the 46 standard-therapy patients (Table 4).
Other outcomes
Net clinical benefit (i.e. the combination of the primary
efficacy outcome and major bleeding) was more favorable
in the rivaroxaban group: the net clinical benefit outcome
occurred in seven (3.2%) of the 220 rivaroxaban recipients
versus 12 (5.5%) of the 219 standard-therapy recipients,
for a hazard ratio of 0.59 (95% CI 0.23–1.51) (Table 3).
Two (0.9%) patients in the rivaroxaban group developed
another vascular outcome (both ischemic strokes), compared
with two (0.9%) patients in the standard-therapy group
(ischemic stroke and myocardial infarction). Six (2.7%)
patients in the rivaroxaban group and 11 (5.0%) patients
in the standard-therapy group died during the study.
Discussion
This analysis of data from Chinese patients included in the
EINSTEIN DVT and EINSTEIN PE studies [11] showed
similar point estimates of relative efficacy and safety of oral






At least one dose of a study drug
received, n (%)
219 (99.5) 218 (99.5)
Intended duration of treatment, n (%)
3 months 56 (25.5) 55 (25.1)
6 months 131 (59.5) 131 (59.8)
12 months 33 (15.0) 33 (15.1)
Mean study duration, days 198.5 191.3
Mean study treatment duration, days 162.2 155.2
Reasons for premature discontinuation of treatment, n (%)
Any reason 27 (12.3) 37 (16.9)
Adverse event 14 (6.4) 15 (6.8)
Consent withdrawn 5 (2.3) 14 (6.4)
Loss to follow-up 4 (1.8) 3 (1.4)treatment of symptomatic DVT and/or PE, consistent with
results observed in the global studies.
There is an indication that VKAs are dosed more
cautiously in China; the percentage of time spent with
INR value <2.0 was higher compared with global studies
(37% vs. 22%) and the percentage of time spent in the
therapeutic range was lower (52% vs. 62%). Interestingly,
the incidence of major or clinically relevant non-major
bleeding was similar in China compared with the global
study population (9.2% vs. 10.0%) for standard-therapy
recipients, whereas this incidence tended to be lower
(5.9% vs. 9.4%) for rivaroxaban recipients [11]. This
confirms the favorable safety profile of oral rivaroxaban
(compared with standard therapy for the treatment of VTE)
in Chinese patients.Fatal PE 0 0
Death in which PE could not be ruled out 1 0
Non-fatal PE 2 2
Recurrent DVT 4 5
Net clinical benefit: VTE plus major bleeding, n (%) 7 (3.2) 12 (5.5)
Safety
No. of patients, safety population 219 218
First episode of major or clinically relevant
non-major bleeding during treatment, n (%)
13 (5.9) 20 (9.2)




Other non-fatal episode in a critical site 0 1
Intracranial 0 1
Associated with a fall in hemoglobin of
≥2 g/dL, transfusion of ≥2 units, or both
0 2




Number of patients at risk
219 200 194 169 143 138 78 27 27 21 15 14 9
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Figure 1 Kaplan–Meier curve for cumulative event rate for treatment-emergent major and clinically relevant non-major bleeding. VKA,
vitamin K antagonist.
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3.2% of patients in the rivaroxaban group and 3.2% of
those in the standard-therapy group. These rates were
slightly higher than in the global study (2.1% and 2.3%
for rivaroxaban and standard therapy, respectively).
There has been a traditional perception that, because of
ethnic differences, Chinese people do not develop VTE
at the same rate as Caucasians. However, although inci-
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*Defined as age >75 years, creatinine clearance <50 mL/min, and/or body weight ≤are unknown, some published studies suggest that the
incidence of VTE in hospitalized medically ill patients is
similar in these ethnic groups [12,13]. Regardless of the
rates of VTE, the standard of care in China is the same
as the standard therapy used in the EINSTEIN program,
i.e. low-molecular-weight heparin overlapping with and
followed by an adjusted-dose VKA. Consistent with the glo-
bal data, rivaroxaban showed similar efficacy to standard
therapy in the Chinese patient population, with a tendencybleeding according to subgroups
Rivaroxaban n/N (%) Standard therapy n/N (%)
7/134 (5.2) 5/133 (3.8)
3/52 (5.8) 9/57 (15.8)
3/33 (9.1) 6/28 (21.4)
8/117 (6.8) 4/116 (3.4)
3/75 (4.0) 10/72 (13.9)
1/19 (5.3) 6/28 (21.4)
0/3 2/11 (18.2)
9/134 (6.7) 14/134 (10.4)
3/79 (3.8) 4/69 (5.8)
0/1 0/4
9/174 (5.2) 13/172 (7.6)
4/45 (8.9) 7/46 (15.2)
50 kg.
Wang et al. Thrombosis Journal 2013, 11:25 Page 7 of 8
http://www.thrombosisjournal.com/content/11/1/25towards an improved safety profile, as demonstrated by the
lower incidence of major and clinically relevant non-major
bleeding complications, a result that was also observed in
frail patients.
A number of studies have shown that Chinese patients
have lower warfarin requirements to achieve a target
INR range, indicating that Chinese patients may have an
increased sensitivity to the anticoagulant effect of VKAs
compared with Caucasians [14]. This sensitivity to war-
farin has not been definitively linked to higher rates of
bleeding in Chinese patients, and little is known about
the optimal intensity of anticoagulation. The few studies
that have assessed whether bleeding on anticoagulation
is similar in Chinese and Caucasian patients have shown
mixed results, were retrospective, and included small
numbers of patients [15,16]. In the global studies, there
is an indication that Chinese doctors give VKAs in dos-
ages aimed to obtain a slightly lower INR. This did not
affect the more favorable bleeding profile of rivaroxaban.
Conclusions
In summary, the results of this analysis of the patients
included in China in the EINSTEIN DVT and EINSTEIN
PE trials show that the performance of rivaroxaban was
consistent with that observed in the global population,
with a similar efficacy and a better bleeding profile to stand-
ard therapy of enoxaparin overlapping with and followed
by a VKA. The data indicate that oral rivaroxaban provides
a new, improved option for the treatment of DVT and PE
in Chinese patients.
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